Sign inCreate account

Report workspace tools

NCT04544293ACTIVE_NOT_RECRUITINGanonymous

A Randomized, Double-blind, Placebo-controlled Clinical Trial of Once-daily Inhaled Molgramostim Nebulizer Solution in Adult Subjects With Autoimmune Pulmonary Alveolar Proteinosis (aPAP)

Sponsor

Source record

Savara Inc.

Phase

Source record

PHASE3

Modality

AI-normalized

small molecule

Target

AI-normalized

Molgramostim, Placebo, Molgramostim Open-label

Indication / condition

AI-normalized

Autoimmune Pulmonary Alveolar Proteinosis

Intervention

Source record

Molgramostim, Placebo, Molgramostim Open-label

Source & freshness

Source record

NCT ID

NCT04544293

Original source

ClinicalTrials.gov

Source last updated

Aug 07, 2025

Ingested at

May 21, 2026

Internal sync

May 23, 2026

Model version

trialsignal-ai-v1

Normalized confidence

96%

Validation status

validated

Open original registry record
View original source fields

NCT ID

NCT04544293

Title

A Randomized, Double-blind, Placebo-controlled Clinical Trial of Once-daily Inhaled Molgramostim Nebulizer Solution in Adult Subjects With Autoimmune Pulmonary Alveolar Proteinosis (aPAP)

Sponsor

Savara Inc.

Status

ACTIVE_NOT_RECRUITING

Phase

PHASE3

Condition raw

Autoimmune Pulmonary Alveolar Proteinosis

Condition normalized

Autoimmune Pulmonary Alveolar Proteinosis

Modality raw

small molecule

Modality normalized

small molecule

Target raw

Molgramostim, Placebo, Molgramostim Open-label

Target normalized

Molgramostim, Placebo, Molgramostim Open-label

Interventions

Molgramostim, Placebo, Molgramostim Open-label

Public preview

Source record

160 subjects with autoimmune pulmonary alveolar proteinosis (aPAP) will be randomized to receive once daily treatment with inhaled molgramostim (MOL) or placebo (PBO) for 48 weeks. Subjects completing the 48-week placebo-controlled period will receive open-label treatment with once daily inhaled molgramostim for 96 weeks.

AI-generated analysis supports research triage only. Verify source records, publications, sponsor disclosures and IP databases before making diligence decisions. Model: trialsignal-ai-v1.

Report access

Create an account to unlock this report

Choose the access model that matches the job: one urgent report, reusable credits for project work, or unlimited monthly access with AI and folders.

Full protocol, outcomes, eligibility, contacts and results sections
Patent/IP landscape with verified records when available
Board-ready PDF export with source provenance
Save to folders and synthesize multiple assets in premium workspace
Create account
Sign in

Create a free account first, then unlock a single report, buy credits or subscribe.

TrialSignal

Clinical trial intelligence report

A Randomized, Double-blind, Placebo-controlled Clinical Trial of Once-daily Inhaled Molgramostim Nebulizer Solution in Adult Subjects With Autoimmune Pulmonary Alveolar Proteinosis (aPAP)

Source-linked diligence brief with registry provenance, taxonomy normalization and premium analytical context.

Generated

Jun 13, 2026

NCT ID

NCT04544293

Status

ACTIVE_NOT_RECRUITING

Phase

PHASE3

Sponsor

Savara Inc.

Executive brief

Investment-Ready Snapshot

160 subjects with autoimmune pulmonary alveolar proteinosis (aPAP) will be randomized to receive once daily treatment with inhaled molgramostim (MOL) or placebo (PBO) for 48 weeks. Subjects completing the 48-week placebo-controlled period will receive open-label treatment with once daily inhaled molgramostim for 96 weeks.

Source & freshness

Provenance

SourceClinicalTrials.gov
Source updatedAug 07, 2025
Internal syncMay 23, 2026
Model versiontrialsignal-ai-v1

https://clinicaltrials.gov/study/NCT04544293

Indication

Autoimmune Pulmonary Alveolar Proteinosis

Modality

small molecule

Target

Molgramostim, Placebo, Molgramostim Open-label

Intervention

Molgramostim, Placebo, Molgramostim Open-label

Source record

Protocol Description

Detailed source ingestion pending.

Source record

Outcome Measures

Detailed source ingestion pending.

Source record

Eligibility

Detailed source ingestion pending.

AI analysis

Known Results And Readout Context

Detailed source ingestion pending.

IP intelligence

Patent And IP Landscape

Detailed source ingestion pending.

Source record

Contacts

Detailed source ingestion pending.